Background: Lung cancer has become the prominent cause of the cancer-related deaths globally. More than 80
% of all lung cancers have been diagnosed with Non- Small Cell Lung Cancer (NSCLC). The USFDA approved osimertinib
to treat patients with metastatic T790M EGFR NSCLC on a regular basis in March 2017. Recently, C797S mutation to
osimertinib has been reported, which indicates the need for structural modification to overcome the problem of mutation.
Objective: In this bioinformatics study, we have evaluated the impact of various acrylamide as an electrophilic warhead on
the activity and selectivity of osimertinib.
Result: Osimertinib analouge 48, 50, 60, 61, 67, 75, 80, 86, 89, 92, 93, 116 and 124 were the most active and selective
compounds against T790M EGFR mutants compared to Osimertinib.
Conclusion: These compounds also showed less inclination towards WT-EGFR.